Back to Journals » Biologics: Targets and Therapy
Biologics: Targets and Therapy
- View all (605)
- Volume 20, 2026 (18)
- Volume 19, 2025 (56)
- Volume 18, 2024 (35)
- Volume 17, 2023 (17)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Journal Articles:
Efficacy, Safety, and Cost-Effectiveness of the Infliximab Biosimilar GP-1111 in Patients with Inflammatory Bowel Disease Who Underwent a Nonmedical Switch: A Prospective Cohort Study
Pápista M, Resál T, Bacsur P, Kata D, Farkas B, Bálint A, Fábián A, Bor R, Ivány E, Szepes Z, Farkas K, Juhász Z, Buzás N, Molnár T
Biologics: Targets and Therapy 2025, 19:731-743
Published Date: 18 December 2025
Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study
Ancona S, Armstrong K, Longo C, Rabone R, Merrick V, Henderson P, Gandullia P, Wilson DC, Arrigo S, Russell RK
Biologics: Targets and Therapy 2025, 19:265-279
Published Date: 29 April 2025
Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging Technologies
Ranbhor R
Biologics: Targets and Therapy 2025, 19:177-187
Published Date: 9 April 2025
Evaluating Biosimilar Development Projects: An Analytical Framework Utilizing Net Present Value
Ranbhor R, Kulkarni P
Biologics: Targets and Therapy 2025, 19:125-135
Published Date: 25 March 2025
Comparison of Innovative and Conventional Methods in Biosimilar Bridging Studies with Multiple References
Pong A, Chow SS, Chow SC
Biologics: Targets and Therapy 2024, 18:377-387
Published Date: 6 December 2024